+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Active, Not Recruiting

Phase 3
Age: 18Years +
All Genders
ID06525220

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1 Head and Neck Squamous Cell Carcinoma

Led by Genmab · Updated on 2026-11-02

699

Participants Needed

202

Research Sites

130 weeks

Total Duration

AI-Summary

What This Trial Is About

This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

CONDITIONS

Brief Title

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here